Pyruvate synthase
| pyruvate synthase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC number | 1.2.7.1 | ||||||||
| CAS number | 9082-51-3 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| Gene Ontology | AmiGO / EGO | ||||||||
| |||||||||
In enzymology, a pyruvate synthase (EC 1.2.7.1) is an enzyme that catalyzes the interconversion of pyruvate and acetyl-CoA. It is also called pyruvate:ferredoxin oxidoreductase (PFOR).
The relevant equilibrium catalysed by PFOR is:
- pyruvate + CoA + oxidized ferredoxin acetyl-CoA + CO2 + reduced ferredoxin + 2 H+
The 3 substrates of this enzyme are pyruvate, CoA, and oxidized ferredoxin, whereas its 4 products are acetyl-CoA, CO2, reduced ferredoxin, and H+.
Function
This enzyme participates in 4 metabolic pathways: pyruvate metabolism, propanoate metabolism, butanoate metabolism, and reductive carboxylate cycle (CO2 fixation).
Its major role is the extraction of reducing equivalents by the decarboxylation. In aerobic organisms, this conversion is catalysed by pyruvate dehydrogenase, also uses thiamine pyrophosphate but relies on lipoate as the electron acceptor. Unlike the aerobic enzyme complex PFOR transfers reducing equivalents to flavins or iron-sulflur clusters. This process links glycolysis to the Wood–Ljungdahl pathway.
Nomenclature
This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with an iron-sulfur protein as acceptor. The systematic name of this enzyme class is pyruvate:ferredoxin 2-oxidoreductase (CoA-acetylating). Other names in common use include:
- pyruvate oxidoreductase,
- pyruvate synthetase,
- pyruvate:ferredoxin oxidoreductase, and
- pyruvic-ferredoxin oxidoreductase.
Inhibitors
- Nitazoxanide is a broad-spectrum antiparasitic drug and FDA-approved PFOR inhibitor which is used for the treatment of Giardiasis and Cryptosporidiosis.[1][2]
- Tizoxanide, an active metabolite of nitazoxanide
- Amixicile, a water-soluble derivative of nitazoxanide, is a potent inhibitor of pyruvate:ferredoxin oxidoreductase and is in pre-clinical studies to treat infections of Helicobacter pylori and Clostridium difficile.[3][4]
References
- ↑ Di Santo N, Ehrisman J (2013). "Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?". Cancers (Basel). 5 (3): 1163–1176. doi:10.3390/cancers5031163. PMC 3795384
. PMID 24202339. Nitazoxanide [NTZ: 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide] is a thiazolide antiparasitic agent with excellent activity against a wide variety of protozoa and helminths. ... Nitazoxanide (NTZ) is a main compound of a class of broad-spectrum anti-parasitic compounds named thiazolides. It is composed of a nitrothiazole-ring and a salicylic acid moiety which are linked together by an amide bond ... NTZ is generally well tolerated, and no significant adverse events have been noted in human trials [13]. ... In vitro, NTZ and tizoxanide function against a wide range of organisms, including the protozoal species Blastocystis hominis, C. parvum, Entamoeba histolytica, G. lamblia and Trichomonas vaginalis [13]
- ↑ "Nitazoxanide Prescribing Information" (PDF). United States Food and Drug Administration. Romark Pharmaceuticals. 3 March 2004. pp. 1–9. Retrieved 3 January 2016.
- ↑ Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS (August 2012). "Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model". Antimicrob. Agents Chemother. 56 (8): 4103–11. doi:10.1128/AAC.00360-12. PMC 3421617. PMID 22585229.
- ↑ Hoffman PS, Bruce AM, Olekhnovich I, Warren CA, Burgess SL, Hontecillas R, Viladomiu M, Bassaganya-Riera J, Guerrant RL, Macdonald TL (2014). "Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori". Antimicrob. Agents Chemother. 58 (8): 4703–12. doi:10.1128/AAC.03112-14. PMC 4136022. PMID 24890599.
Further reading
- Evans MC, Buchanan BB (1965). "Photoreduction of ferredoxin and its use in carbon dioxide fixation by a subcellular system from a photosynthetic bacterium". Proc. Natl. Acad. Sci. U.S.A. 53 (6): 1420–5. doi:10.1073/pnas.53.6.1420. PMC 219872. PMID 5217644.
- Gehring U, Arnon DI (1972). "Purification and properties of -ketoglutarate synthase from a photosynthetic bacterium". J. Biol. Chem. 247 (21): 6963–9. PMID 4628267.
- Uyeda K, Rabinowitz JC (1971). "Pyruvate-ferredoxin oxidoreductase. 3. Purification and properties of the enzyme". J. Biol. Chem. 246 (10): 3111–9. PMID 5574389.
- Uyeda K, Rabinowitz JC (1971). "Pyruvate-ferredoxin oxidoreductase. IV. Studies on the reaction mechanism". J. Biol. Chem. 246 (10): 3120–5. PMID 4324891.
- Charon MH, Volbeda A, Chabriere E, Pieulle L, Fontecilla-Camps JC (1999). "Structure and electron transfer mechanism of pyruvate:ferredoxin oxidoreductase". Curr. Opin. Struct. Biol. 9 (6): 663–9. doi:10.1016/S0959-440X(99)00027-5. PMID 10607667.